Non‑conventional Fotemustine Schedule as Second‑line Treatment in Recurrent Malignant Gliomas: Survival Across Disease and Treatment Subgroup Analysis and Review of the Literature

Molecular and Clinical Oncology - United Kingdom
doi 10.3892/mco.2018.1746

Related search